170 related articles for article (PubMed ID: 9382165)
1. Cyclosporine dose adjustment using levels obtained six hours after the morning dose: effect on side effects in patients with autoimmune diseases.
Cantarovich M; Deschênes J
Am J Nephrol; 1997; 17(5):450-7. PubMed ID: 9382165
[TBL] [Abstract][Full Text] [Related]
2. Renal function and blood pressure in patients receiving long-term, low-dose cyclosporine therapy for idiopathic autoimmune uveitis.
Deray G; Benhmida M; Le Hoang P; Maksud P; Aupetit B; Baumelou A; Jacobs C
Ann Intern Med; 1992 Oct; 117(7):578-83. PubMed ID: 1524331
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and side-effects of cyclosporine dose monitoring with levels 6 h after the morning dose in heart transplant patients.
Cantarovich M; Besner JG; Fitchett DH; Latter DA
Clin Transplant; 1997 Oct; 11(5 Pt 1):399-405. PubMed ID: 9361930
[TBL] [Abstract][Full Text] [Related]
4. Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study.
Isnard Bagnis C; Tezenas du Montcel S; Beaufils H; Jouanneau C; Jaudon MC; Maksud P; Mallet A; LeHoang P; Deray G
J Am Soc Nephrol; 2002 Dec; 13(12):2962-8. PubMed ID: 12444215
[TBL] [Abstract][Full Text] [Related]
5. Cyclosporine monitoring with levels 6 hours after the morning dose in patients with noninfectious uveitis.
Rocha G; Deschênes J; Cantarovich M
Ophthalmology; 1997 Feb; 104(2):245-51. PubMed ID: 9052628
[TBL] [Abstract][Full Text] [Related]
6. Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy.
Mourad G; Vela C; Ribstein J; Mimran A
Transplantation; 1998 Mar; 65(5):661-7. PubMed ID: 9521200
[TBL] [Abstract][Full Text] [Related]
7. Renal outcome after ciclosporin-induced nephrotoxicity.
Tostivint I; du Montcel ST; Jaudon MC; Mallet A; Le Hoang P; Bodaghi B; Deray G; Bagnis CI
Nephrol Dial Transplant; 2007 Mar; 22(3):880-5. PubMed ID: 17127700
[TBL] [Abstract][Full Text] [Related]
8. Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients.
Chanard J; Toupance O; Lavaud S; Hurault de Ligny B; Bernaud C; Moulin B
Nephrol Dial Transplant; 2003 Oct; 18(10):2147-53. PubMed ID: 13679494
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients.
White M; Pelletier GB; Tan A; Jesina C; Carrier M
J Heart Lung Transplant; 1997 Aug; 16(8):787-94. PubMed ID: 9286770
[TBL] [Abstract][Full Text] [Related]
10. An improved glomerular filtration rate in cardiac transplant recipients with once-a-day cyclosporine dosing.
Bunke M; Sloan R; Brier M; Ganzel B
Transplantation; 1995 Feb; 59(4):537-40. PubMed ID: 7878758
[TBL] [Abstract][Full Text] [Related]
11. Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients.
Bertoni E; Larti A; Rosso G; Zanazzi M; Di Maria L; Salvadori M
J Nephrol; 2011; 24(5):613-8. PubMed ID: 21240873
[TBL] [Abstract][Full Text] [Related]
12. Conversion from cyclosporine to sirolimus in chronic renal allograft dysfunction: a 4-year prospective study.
Han F; Wu J; Huang H; Zhang X; He Q; Wang Y; Wang S; Wang H; Chen J
Exp Clin Transplant; 2011 Feb; 9(1):42-9. PubMed ID: 21605022
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin converting enzyme inhibition and chronic cyclosporine-induced renal dysfunction in type 1 diabetes.
Hannedouche TP; Natov S; Boitard C; Lacour B; Grünfeld JP
Nephrol Dial Transplant; 1996 Apr; 11(4):673-8. PubMed ID: 8671857
[TBL] [Abstract][Full Text] [Related]
14. Cyclosporine A-induced nephrotoxicity is ameliorated by dose reduction and conversion to sirolimus in the rat.
Sereno J; Vala H; Nunes S; Rocha-Pereira P; Carvalho E; Alves R; Teixeira F; Reis F
J Physiol Pharmacol; 2015 Apr; 66(2):285-99. PubMed ID: 25903959
[TBL] [Abstract][Full Text] [Related]
15. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.
Oberbauer R; Kreis H; Johnson RW; Mota A; Claesson K; Ruiz JC; Wilczek H; Jamieson N; Henriques AC; Paczek L; Chapman J; Burke JT;
Transplantation; 2003 Jul; 76(2):364-70. PubMed ID: 12883194
[TBL] [Abstract][Full Text] [Related]
16. Administration of low-dose cyclosporine alone for the treatment of elderly patients with membranous nephropathy.
Li MX; Yu YW; Zhang ZY; Zhao HD; Xiao FL
Genet Mol Res; 2015 Mar; 14(1):2665-73. PubMed ID: 25867415
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled trial of verapamil on cyclosporine nephrotoxicity in heart and lung transplant recipients.
Chan C; Maurer J; Cardella C; Cattran D; Pei Y
Transplantation; 1997 May; 63(10):1435-40. PubMed ID: 9175807
[TBL] [Abstract][Full Text] [Related]
18. Glomerular and tubular function in renal transplant patients treated with and without ciclosporin A.
Hansen JM; Fogh-Andersen N; Leyssac PP; Strandgaard S
Nephron; 1998 Dec; 80(4):450-7. PubMed ID: 9832645
[TBL] [Abstract][Full Text] [Related]
19. Adverse effects of low-dose systemic cyclosporine therapy in high-risk penetrating keratoplasty.
Lee JJ; Kim MK; Wee WR
Graefes Arch Clin Exp Ophthalmol; 2015 Jul; 253(7):1111-9. PubMed ID: 25896110
[TBL] [Abstract][Full Text] [Related]
20. Single daily dose of cyclosporine in patients with primary glomerulonephritis and nephrotic syndrome.
Rasche FM; Keller F; Kunze G; Boesler B; Czock D
Clin Nephrol; 2007 May; 67(5):285-92. PubMed ID: 17542337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
